Literature DB >> 25065665

Sinonasal eosinophilic angiocentric fibrosis: a systematic review.

Christina H Fang1, Leila J Mady, Neena M Mirani, Soly Baredes, Jean Anderson Eloy.   

Abstract

BACKGROUND: Eosinophilic angiocentric fibrosis (EAF) is a benign rare lesion of the upper respiratory mucosa. EAF most commonly presents with an obstructive nasal mass. Due to the rarity of EAF, case reports and case studies have predominated the literature. This systematic review discusses the demographics, clinical presentation, associated findings, management, and outcomes of this uncommon entity.
METHODS: The PubMed database was searched for all articles describing patients diagnosed with sinonasal EAF. Additional cases were examined from the bibliographies of selected articles. Demographics, clinical presentation, associated findings, radiography, management, and outcome were analyzed.
RESULTS: Fifty-two cases were included from 34 articles, including 1 case from our institution. The most common presenting symptom was nasal obstruction (78.8%). Fourteen patients (26.9%) had a previous history of nasal surgery or trauma. Surgical resection alone was the most commonly used primary treatment approach (50.0%), resulting in the greatest proportion of disease-free patients (55.6%) over a median follow-up period of 36 months. A combination of surgery and corticosteroids was the second-most-common treatment modality, used in 28.8% of cases. Of the 40 cases reporting patient outcomes, 100% of patients were alive at follow-up independent of treatment modality.
CONCLUSION: To date, this review contains the largest number of patients with sinonasal EAF. Aggressive surgical resection alone constitutes the most common treatment modality and may be most effective at eradicating disease.
© 2014 ARS-AAOA, LLC.

Entities:  

Keywords:  angiocentric fibrosis; eosinophilic angiocentric fibrosis; nasal eosinophilic angiocentric fibrosis; sinonasal mass; sinus; sinus eosinophilic angiocentric fibrosis

Mesh:

Year:  2014        PMID: 25065665     DOI: 10.1002/alr.21347

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  8 in total

1.  Nasal Framework Reconstruction in Patient with Eosinophilic Angiocentric Fibrosis.

Authors:  Amir Arvin Sazgar; Sahand Kia; Armin Akbari
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-07-18

Review 2.  The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review.

Authors:  Stephanie S Eng; Magee L DeFelice
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

3.  Eosinophilic Angiocentric Fibrosis of Sinonasal Region: A Rare & Under Reported Entity.

Authors:  Aminder Singh; Pavneet Kaur Selhi; Manish Munjal; Neena Sood
Journal:  J Clin Diagn Res       Date:  2015-11-01

4.  Neoadjuvant use of methotrexate in eosinophilic angiocentric fibrosis of upper lip and hard palate: A case report.

Authors:  Francesca Nastro; Angelo Ruggiero; Gustavo Spanò; Sara Cacciapuoti; Mariateresa Cantelli; Gabriella Fabbrocini; Claudio Marasca
Journal:  Dermatol Ther       Date:  2021-08-13       Impact factor: 3.858

5.  An unusual presentation of eosinophilic angiocentric fibrosis.

Authors:  Joel Hardman; Christopher Toon; Arjuna Nirmalananda
Journal:  J Surg Case Rep       Date:  2017-12-08

6.  Eosinophilic Angiocentric Fibrosis in Bilateral Upper Eyelid Conjunctivas: A First Case Report.

Authors:  Sho Okuyama; Hiroyuki Yazu; Yumi Ito; Hiroshi Minato; Hiroshi Fujishima
Journal:  Am J Case Rep       Date:  2020-05-05

7.  Diagnostic dilemmas of mechanical restriction of the medial rectus: A case report.

Authors:  James A Gallogly; Farhoud Faraji; Mejd H Jumaily; John S Schneider; Joseph D Brunworth
Journal:  Allergy Rhinol (Providence)       Date:  2018-04-12

Review 8.  Eosinophilic angiocentric fibrosis of the sinonasal tract: a case report and review of the literature.

Authors:  Etrat Javadirad; Narges Eskandari Roozbahani; Sepehr Sadafi
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.